144
IRUS TotalDownloads
Altmetric
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
File | Description | Size | Format | |
---|---|---|---|---|
s41467-020-18130-3.pdf | Published version | 1.07 MB | Adobe PDF | View/Open |
Title: | A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics |
Authors: | Crone, M Priestman, M Ciechonska, M Jensen, K Sharp, D Anand, A Randell, P Storch, M Freemont, P |
Item Type: | Journal Article |
Abstract: | The SARS-CoV-2 pandemic has shown how a rapid rise in demand for patient and community sample testing can quickly overwhelm testing capability globally. With most diagnostic infrastructure dependent on specialized instruments, their exclusive reagent supplies quickly become bottlenecks, creating an urgent need for approaches to boost testing capacity. We address this challenge by refocusing the London Biofoundry onto the development of alternative testing pipelines. Here, we present a reagent-agnostic automated SARS-CoV-2 testing platform that can be quickly deployed and scaled. Using an in-house-generated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well as two detection assays based on CRISPR-Cas13a and RT-loop-mediated isothermal amplification (RT-LAMP). In collaboration with an NHS diagnostic testing lab, we report the performance of the overall workflow and detection of SARS-CoV-2 in patient samples using RT-qPCR, CRISPR-Cas13a, and RT-LAMP. The validated RNA extraction and RT-qPCR platform has been installed in NHS diagnostic labs, increasing testing capacity by 1000 samples per day. |
Issue Date: | 8-Sep-2020 |
Date of Acceptance: | 5-Aug-2020 |
URI: | http://hdl.handle.net/10044/1/81660 |
DOI: | 10.1038/s41467-020-18130-3 |
ISSN: | 2041-1723 |
Publisher: | Nature Research |
Start Page: | 1 |
End Page: | 11 |
Journal / Book Title: | Nature Communications |
Volume: | 11 |
Copyright Statement: | © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. |
Sponsor/Funder: | Engineering & Physical Science Research Council (E Engineering & Physical Science Research Council (EPSRC) Biotechnology and Biological Sciences Research Council (BBSRC) NPL Management Limited UK DRI Ltd |
Funder's Grant Number: | RG91264 EP/S001859/1 BB/M025632/1 N/A 'CR & T IMP' |
Publication Status: | Published |
Article Number: | 4464 |
Online Publication Date: | 2020-09-08 |
Appears in Collections: | Department of Infectious Diseases Faculty of Medicine Imperial College London COVID-19 Department of Brain Sciences |
This item is licensed under a Creative Commons License